Latest News and Press Releases

LEIDEN, the Netherlands, Oct. 06, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...

Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.A clinically meaningful improvement of CF respiratory...

Key updates ProQR presents in vivo data in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer® RNA editing platform technology.Axiomer® technology Editing...

LEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of...

Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation from the FDA, representing the fifth program in the Company’s pipeline to receive...

Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors.As part of the transaction, ProQR has granted an exclusive...

Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the...

Key Updates Last patient received their final dose in the PQ-010-001 Phase 1b clinical trial of QR-010 in CF patients with the F508del mutation.Top-line trial data are expected to be issued in a...

Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the...

Key updates Data from two clinical trials of QR-010 presented at the European Cystic Fibrosis Conference.  Enrollment completed in the Phase 1b clinical trial in cystic fibrosis (CF) and top-line...